Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2012-10-01 / Immunotherapy 2012 Oct;4(10):995-1009Immunotherapy in ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2012-08-21 / Hum Vaccin Immunother 2012 Sep;8(9):1179-91Successful treatment of advanced ovarian cancer with thermochemotherapy and adjuvant immune therapy
/in Dendritic Cells, Hyperthermia, International Publications, Ovarian Cancer /von 2012-05-05 / Case Rep Oncol 2012 May;5(2):212-5Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2012-04-05 / Cancer Immunol. Immunother. 2012 Nov;61(11):1929-39Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses
/in Hyperthermia, International Publications, Ovarian Cancer /von 2012-02-13 / Toxicol. Sci. 2012 May;127(1):139-49Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2011-10-22 / Cancer Immunol. Immunother. 2012 May;61(5):629-41A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2011-09-17 / Cancer Immunol. Immunother. 2012 Mar;61(3):373-84Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2011-07-01 / Immunotherapy 2011 Jul;3(7):805-7Dendritic cell vaccination against ovarian cancer–tipping the Treg/TH17 balance to therapeutic advantage?
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2011-01-28 / Expert Opin Biol Ther 2011 Apr;11(4):441-5IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de